ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferon"

  • Abstract Number: 2540 • ACR Convergence 2024

    Characterizing the Functional Role of Type I Interferons in Inflammatory Arthritis

    Mary Huang, Richard Bell, Toolika Singh and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation due to cellular infiltration and inflammatory mediators. Type I interferons (IFN) have…
  • Abstract Number: 0093 • ACR Convergence 2024

    Overexpression of Epidermal Ifnk Promotes Systemic CD8+ T Cell Maturation After UV-exposure

    Benjamin Klein1, Kelsey E. McNeely2, Debbie Colesa2, Yiqing Gao2, Nguyen Thi Kim Nguyen2, Johann Gudjonsson1 and J. Michelle Kahlenberg1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan Michigan Medicine, Ann Arbor, MI

    Background/Purpose: Skin involvement is the most common organ manifestation in systemic lupus erythematosus (SLE), and exacerbation of cutaneous lupus (CLE) can precede systemic disease flares.…
  • Abstract Number: 1430 • ACR Convergence 2024

    C57BL/6.NOD-Aec1Aec2 Mice Recapitulate Sjögren’s Serology Better Than NOD.B10Sn-H2b Models and JAK Inhibitor Treatment Improves Immunoglobulins and Salivary Gland Inflammation but Not Salivary Flow in Sjögren’s Mice

    Sara McCoy1 and Ilya Gurevic2, 1University of Wisconsin, Middleton, WI, 2University of Wisconsin, Madison

    Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease in which interferons (IFNs) are believed to play a major role/ JAK inhibitors (JAKinibs) block IFN…
  • Abstract Number: 1793 • ACR Convergence 2024

    SLE Patient Serum and SLE-associated Danger Signals Impair Efferocytosis in Human Macrophages

    Jessica Shannon and Rafael de Queiroz Prado, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Efficient clearance of apoptotic cells, known as efferocytosis, plays a pivotal role in maintaining self-tolerance. Dysfunction in efferocytosis is implicated in the pathogenesis of…
  • Abstract Number: 2547 • ACR Convergence 2024

    Neurophysiological Phenotypes Are Uncoupled from Toll-like Receptor-Mediated Peripheral Disease in a Mouse Model of Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

    Cecilia Stumpf1, Vanessa Rodriguez1 and Carla Cuda2, 1Northwestern University, Chicago, 2Northwestern University, Chicago, IL

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical presentations, including neuropsychiatric symptoms (NPSLE). Despite being a major cause of morbidity…
  • Abstract Number: 0328 • ACR Convergence 2024

    IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease

    Melissa Leeolou1, Lorinda Chung2, Kavita Sarin3 and david fiorentino4, 1Stanford University School of Medicine, Redwood City, CA, 2Stanford University, Woodside, CA, 3Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, 4Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA

    Background/Purpose: Type I interferon (IFN) plays a role in the pathogenesis of dermatomyositis (DM) and correlates with measures of disease activity.  Melanoma differentiation-associated gene 5…
  • Abstract Number: 1497 • ACR Convergence 2024

    Type I Interferon Status and Clinical Manifestations in a Large Cohort of Patients with Systemic Lupus Erythematosus

    Justin Smith1, Laura Patricia Whittall Garcia2, Dennisse Bonilla2, Qixuan Li2, Robert Terbrueggen3, Hemani Wijesuriya3, Ian Richards3, Aviva Jacobs3, Joan Wither2, Dafna Gladman4 and Zahi Touma5, and DxTerity, 1University of Toronto, Toronto, AB, Canada, 2University Health Network, Toronto, ON, Canada, 3DxTerity Diagnostics Inc., Torrance, CA, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada

    Background/Purpose: Type I interferons (IFN) are pivotal in the pathogenesis of SLE, with studies showing high IFN gene signature (IGS) status associated with certain organ…
  • Abstract Number: 1800 • ACR Convergence 2024

    WWC1 Regulates Type I Interferon Production Through Modulation of cGAS-STING Signaling in Keratinocytes

    Bin Xu, Laura Cencer, Benjamin Klein, Shannon Loftus, Lam Tsoi, Johann Gudjonsson and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Our recent study uncovered a role for dysregulation of the Hippo signaling pathway in systemic lupus erythematosus (SLE) keratinocytes (KCs) driven by overexpression of…
  • Abstract Number: 2549 • ACR Convergence 2024

    VISTA Deficiency Alters the Skin Immune Cell Composition and Confers Skin Sensitivity to UV Light

    Zachary Peters1, Lindsay Mendyka2, Angelique Cortez1, J'voughnn Blake1, Alecia Roy1, William Rigby3, Christopher Burns4, Randolph Noelle5 and Sladjana Skopelja-Gardner6, 1Dartmouth College, Lebanon, NH, 2Dartmouth Hitchcock Memorial Hospital, Lyme, NH, 3Dartmouth-Hitchcock, Norwich, VT, 4Dartmouth Hitchcock Medical Center, Lebanon, NH, 5Geisel School of Medicine at Dartmouth, Lebanon, 6Dartmouth Geisel School of Medicine, Lebanon, NH

    Background/Purpose: Persistent production of type I interferons (IFN-Is) is one of the hallmarks of cutaneous lupus erythematosus (CLE) that is exacerbated by ultraviolet (UV) light.…
  • Abstract Number: 0617 • ACR Convergence 2024

    Hereditary C1q Deficiency Is Associated with Type 1 Interferon-pathway Activation and a High Risk of Central Nervous System Inflammation

    Clément triaille1, Neha Mohan Rao2, Gillian Rice3, Luis Seabra4, Sutherland Fraser5, Vincent Bondet6, Darragh duffy6, Andrew Gennery7, Benjamin Fournier8, Brigitte Bader-Meunier9, Christopher Troedson10, Gavin CLeary11, Helena Buso12, Jacqueline Dalby-Payne13, Ranade Prajakta14, Katrien Jansen15, Lien De Somer16, Marie-Louise Fremond17, Pimple Pallavi14, Melanie Wong18, Russel Dale10, Carine Wouters16, PIERRE QUARTIER19, Raju Khubchandani20 and Yanick Crow5, 1Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Brussels, Belgium, 2NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, 3Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, 4Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France, Paris, France, 5MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom, Edinburgh, United Kingdom, 6Translational Immunology Unit, Institut Pasteur, Université Paris-Cité, Paris, France, Paris, France, 7: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, Newcastle, United Kingdom, 8Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, France, 9Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, 10T. Y. Nelson Department of Neurology and Neurosurgery, Children's Hospital at Westmead, Westmead, New South Wales, and University of Sydney, Australia, Sydney, Australia, 11: Paediatric Rheumatology, Alder Hey Children's Hospital, Liverpool, United Kingdom, Liverpool, United Kingdom, 12Department of Medicine - DIMED, University of Padova, Padova, Italy, Padova, Italy, 13Specialty of Child and Adolescent Health, Faculty of Medicine, The University of Sydney, Australia, Sydney, Australia, 14NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, India, 15Division of Pediatric Neurology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, 16Division of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, 17Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, United Kingdom, 18Department of Allergy and Immunology, Children's Hospital at Westmead, Westmead, Australia, Westmead, Australia, 19Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France, 20SRCC Childrens Hospital, Mumbai, India

    Background/Purpose: To report on the largest cohort of C1Q deficient (C1QDef ) patients; to investigate the activation of Type 1 interferon pathway in the blood…
  • Abstract Number: 1507 • ACR Convergence 2024

    To Develop a Method for Estimating Interferon Signatures in SLE from Routine Clinical Laboratory Tests

    Yoshinobu Koyama1, Yoshiharu Sato2, Yu Nakai1 and Moe Tokunaga3, 1Japanese Red Cross Okayama Hospital, Okayama, Japan, 2DNA Chip Research Inc., Tokyo, 3Japanese Red Cross Okayama Hospital, Okayama

    Background/Purpose: IFN signatures are known to play an important role in the pathogenesis of systemic autoimmune diseases such as SLE. Recently, therapeutic agents targeting IFN…
  • Abstract Number: 1807 • ACR Convergence 2024

    Identification of HDAC Inhibitor Targeting Type I Interferon and B-cell Abnormalities in Systemic Lupus Erythematosus

    Takehiro Hirayama1, Hyota Takamatsu2 and Atsushi Kumanogoh3, 1Osaka university, ibaraki city, Japan, 2National Hospital Organization Osaka Minami Medical Center, kawachinagano, Japan, 3Osaka University, Osaka, Japan

    Background/Purpose: This study aimed to identify drugs that can inhibit both type I interferon (IFN-I) production and abnormal B-cell maturation and to elucidate the therapeutic…
  • Abstract Number: 2678 • ACR Convergence 2024

    History of Cutaneous Lupus Promotes Blood and Skin Interferon Signatures in SLE Patients

    Svenja Henning1, Lam Tsoi2, Craig Dobry2, Celine Berthier2, Benjamin Klein2, Amy Hurst2, Rachael Wasikowski3, Johann Gudjonsson2 and J. Michelle Kahlenberg2, 1University of Groningen, Groningen, Netherlands, 2University of Michigan, Ann Arbor, MI, 3Michigan, Dept. of Dermatology, Ann Arbor, MI

    Background/Purpose: Cutaneous lupus (CLE) can present in isolation or as one of the most common manifestations of systemic lupus erythematosus (SLE). Interferon (IFN) stimulated genes…
  • Abstract Number: 0633 • ACR Convergence 2024

    Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus

    Wenyan Miao1, Digna de Bruin2, Cedric Arisdakessian1, Jannik Rousel2, Jared Steranka1, Matthijs Moerland2, Eric Jacobson1, Mehrnaz Gharaee-Kermani3, Liyang Diao1, Craig Dobry3, Nafeeza Hafeez1, Brian Desrosiers1, J. Michelle Kahlenberg3, Heike Keilhack1, Robert Rissmann2, Keith M Wilcoxen1 and Tessa Niemeyer-van der Kolk2, 1Rome Therapeutics, Boston, MA, 2Centre for Human Drug Research, Leiden, Netherlands, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Long Interspersed Element-1 (LINE-1) retrotransposon encodes for two proteins, ORF1p and ORF2p. ORF1p is a chaperone protein while ORF2p contains reverse transcriptase (RT) and…
  • Abstract Number: 1537 • ACR Convergence 2024

    Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases

    Kelly A. Pike1, Nadine Fradet1, Samuel Gaudreault1, Alexander M Skeldon2, Ramsay E. Beveridge2, Patrick Cyr2, Nicolas Sgarioto2, Philippe Le Gros3, Eleftheria Seliniotakis2, Valerie Dumais2, Jacklyn Smith2, James I.P Stewart2, Mehrnaz Gharaee-Kermani4, Michelle J Kahlenberg4 and Michael A. Crackower2, 1Ventus Therapeutics, Saint-Laurent, QC, Canada, 2Ventus Therapeutics, Saint-Laurent, Canada, 3Ventus Therapeutics, Montreal, QC, Canada, 4University of Michigan, Ann Arbor, MI

    Background/Purpose: Cyclic GMP-AMP synthase (cGAS) is a nucleic acid sensor that plays a central role in anti-viral responses. Following the detection of intracellular double-stranded DNA,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology